Taxotere is already approved in Japan for the treatment of breast cancer, non-small cell lung, gastric, head and neck, ovarian, esophageal and endometrial cancers.
This new approval is based on the results of an international large-scale Phase III clinical study TAX327 and on a Japanese Phase II clinical trial.